ASSESSING THE RATIONALE OF FDC CONTAINING OFLOXACINS AND AZOLES: DISSOLUTION, PERMEATION AND ANTIMICROBIAL STUDIES
Fixed dose combinations can be useful for the patient if they are being formulated with a rationale. The term ‘rationality’ means the drugs which are been combined has an effective action than their respective individual dose without adverse effects. However, the Indian markets are flooded with irrational and unapproved fixed drug combinations (FDC) drugs owing to lack of control and vague regulations. Currently, this issue of FDC has been addressed properly. In support to the same, we performed a study on antibacterial and antiprotozoal FDC products (ofloxacins and azoles), prescribed for the treatment of diarrhea. Rationality of this combination was verified by assessing parameters such as in vitro dissolution, ex vivo permeation and antimicrobial studies. These studies were performed on individual as well as combination doses for the synergistic effect with comparative study to verify the rationale of FDC formulation.
2. Yadav A., Jeenger J., Panwar D. Evaluation of Rationality of Fixed-Dose Combinations Prescribed in Psychiatric Patients. National Journal of Physiology Pharmacy and Pharmacology 2016; 6(2): 150-154.
3. Ige P. Fixed Dose Combination Product: A Review. Indian Journal of Novel Drug Delivery 2017; 9(1): 1-11.
4. Mcgettigan P., Roderick P., Mahajan R., Kadam A., Pollock A., Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs.Journal of Plos Medicine 2015;12(5):1-28.
6. Gummadi S., Thota D., Yarri S V., Vaddi P., Jillella V L. Development and Validation of UV Spectrophotometric Methods for Simultaneous Estimation of Ciprofloxacin and Tinidazole In Tablet Formulation. International Current Pharmaceutical Journal 2012; 1(10):317-321.
7. Prathyusha V., Abdul Rahaman S.,Revati S., Renuka G. Development and Validation of UV Spectrophotometric Methods for Simultaneous Estimation of Ciprofloxacin and Tinidazole In Tablet Dosage Form. International Journal of Pharmacy and Industrial Research 2013; 03(03):295-300.
8. Choudhary S., Goyal A., and Singh G. Dissolution Development of Ciprofloxacin and Tinidazole in Combined Tablet Dosage Form. International Journal of Pharmacy and Therapeutics 2015; 6(1): 33-36.
9. Bulbule M. and Gangrade D. Simultaneous Estimation of Norfloxacin And Tinidazole InCombined Tablet Dosage Form by Using Rp- Hplc Method. International Journal of Pharmaceutical Sciences and Research, 2017; 8(1): 236-243.
10. Noura H. Abou-Taleb, Dina T.El-Sherbiny, Dalia R. El-Wasseef, Mohamed A. Abu El-Enin, Saadia M. El-Ashry. Simultaneous Determination of Norfloxacin and Tinidazole Binary Mixture by Difference Spectroscopy. International Journal of Biomedical Science 2011; 7(2): 137-144.
11. Nayak K., Khare N., Sayare A., Ghode P., Lawrence R. New validated UV Spectrophotometric Methods for Estimation of Norfloxacin and Tinidazole in bulk and tablet dosage form. Der pharmaciaLettre, 2012; 4(1): 192-198.
12. Shrivastava D., Shrivastava A andPatel R. A Review of Spectrophotometric Determination of Antibiotic Norfloxacin. IJPSR, 2017;8(9):3619-3629.
13. Kothapalli U., Vandana K., Dash A K, T., Harika L., Pradhan K. A Validated UV-Spectrophotometric Method for the Estimation of Tinidazole in Bulk and Pharmaceutical Dosage Form. International Journal of Pharmaceutical and Biological Archives 2011; 2(4):1152-1156.
14. Singh L. Validated Method for Determination of Tinidazole using Direct Colorimetry, UV-visible Spectrophotometry and Difference Spectrophotometry in Pure and Tablet Dosage Form. Journal of Pharmacy Research 2010; 3(6): 1211-1214.
15. Chakrabarti A. Prescription of fixed dose combination drugs for diarrhoea. Indian Journal of Medical Ethics 2007; 4: 165-167.
19. Gautam C., Aditya S. Irrational Drug Combinations: Need to Sensitize Undergraduates. Indian Journal of Pharmacology 2006; 38(3): 169-170.
20. World Health Organisation. Proposal to Waive In Vivo Bioequivalence Requirements for the WHO Model List of Essential Medicines Immediate Release, Solid Oral Dosage Form. QAS/04.109/Rev.1.
21. The Indian Pharmacopoeia. Department of Ministry of Health & Family Welfare. Published by The Indian Pharmacopoeia Commission, Ghaziabad, 2018; Vol. I/II/III:179-181,1630-1631,2750,3381.
22. USFDA Draft Guidance on Tinidazole.2007, Rev 2012.
23. Zakelj S., Sturm K., Kristl A. Ciprofloxacin Permeability and Its Active Secretion Through Rat Small Intestine In Vitro. International Journal of Pharmaceutics, 2006:175-180
24. Mendesa C., Meirellesa G., Silvab M., Ponchela G. Intestinal Permeability Determinants of Nor?oxacin In Ussing Chamber Model. European Journal of Pharmaceutical Sciences, 2018:236-242.
25. Kinh L, Anh D, S Jovel S, and Khue T. Tinidazole Delivery Improved by Nanosized Minicells Originated from Leuconostoc Mesenteroides. Hindawi Journal of Nanomaterials, 2019:1-9.
26. Stahib AH., Beermann D., Harder S., Fuhr U., Liermann D. Absorption Differences of Ciprofloxacin Along the Human Gastrointestinal Tract Determined using A Remote-Control Drug Delivery Device (HF-Capsule). The American Journal of Medicines,1989;87:66-69.
27. Balouri M., Sadiki M., Ibnsouda S. Methods For In Vitro Evaluating Antimicrobial Activity: A Review. Journal of Pharmaceutical Analysis, 2016;1: 71-79.
This work is licensed under a Creative Commons Attribution 4.0 International License.